Dr. McKerracher is Founder and CEO of BioAxone BioSciences, and is a serial entrepreneur who has extensive experience in managing drug discovery, preclinical research and clinical development, including small molecule and protein-based therapeutics. Dr. McKerracher created BioAxone in 2011, after acquiring all rights to a PII biologic drug to treat spinal cord injury. The company is backed by private investors. Dr. McKerracher is a recognized leader in regenerative medicine and translational neuroscience and was a co-recipient of the Christopher Reeve Research Medal for Spinal Cord Repair in 2000. Dr. McKerracher has 15 years’ experience in academic research and left a tenured position to pursue a passion for drug development. Prior to starting BioAxone, Dr. McKerracher was CEO at a genomics company, VP at a Clean-tech company and CSO at her first spin-out biotech company. In 2013 BioAxone was selected as one of 10 Life Sciences to participate in the prestigious Springboard program for women entrepreneurs leading high growth companies.Dr. McKerracher has published over 50 articles in peer-reviewed journals, and has over 15 issued patents. Dr. McKerracher holds a BSc from McGill University, a PhD at York University, and received post-doctoral training at the Worcester Foundation for Experimental Biology (MA) and McGill University.